Aducanumab Panel Pushes Back On Rosy FDA Outlook, Could Derail A Swift Approval
An FDA advisory committee panel were critical of the agency’s review package for Biogen's aducanumab, raising uncertainty about the prospects of approval.
You may also be interested in...
Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
Join us for a brief audio tour around key developments in the global biopharma industry over the past week, in this podcast version of Scrip's Five Must-Know Things.
A look at drugs the agency approved despite an advisory committee vote not to do so and how they compare to Biogen’s Alzheimer’s disease drug aducanumab.